NCT07045532 Assessment the Effectiveness of BTVA in COPD and Ablation in Pulmonary Nodules by Pulmonary MRI
| NCT ID | NCT07045532 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Shanghai Chest Hospital |
| Condition | COPD |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2024-09-01 |
| Primary Completion | 2026-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2024-09-01 with a primary completion date of 2026-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
A Clinical Study Based on Magnetic Resonance Imaging of the Lungs to Assess the Efficacy of Thermal Vapor Ablation and Pulmonary Nodule Ablation in Chronic Obstructive Pulmonary Disease After Surgery. The efficacy of hot steam ablation for chronic obstructive pulmonary disease was evaluated using the innovative MRI sequence PREFUL\_MRI, and the efficacy of pulmonary nodule ablation was evaluated using the innovative MRI sequence GRASP\_MRI.
Eligibility Criteria
Inclusion Criteria: 1. Age \>18 years old; 2. Patients with pulmonary nodules: patients with pulmonary nodules indicated by chest CT, pathologically diagnosed as malignant, and receiving ablative treatment, including transthoracic and percutaneous ablative methods, including radiofrequency, microwave, and freezing; 3. COPD patients: patients diagnosed with COPD according to the GOLD principle and treated with thermal steam ablation for COPD; 4. Understand the study and sign the informed consent. Exclusion Criteria: 1. Chest CT nodules in patients with pulmonary nodules were pure ground glass nodules; 2. Patients who install or carry metal implants such as cardiac pacemakers, heart stents, artificial heart valves in the body or suffer from claustrophobia, allergy to contrast media and other reasons are not suitable for MRI examination; 3. severe cardiopulmonary dysfunction and other diseases that may significantly increase the risk of ablation surgery; 4. Patients with severe COPD exacerbation or pneumonia in the past four weeks;
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07045532 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying COPD. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07045532 currently recruiting?
Yes, NCT07045532 is actively recruiting participants. Contact the research team at sjtuyl@163.com for enrollment information.
Where is the NCT07045532 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT07045532 clinical trial?
NCT07045532 is sponsored by Shanghai Chest Hospital. The trial plans to enroll 100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.